Caroline Palomeque Analyst PerformanceAnalyst at Maxim GroupCaroline Palomeque is a stock analyst at Maxim Group, covering 16 publicly traded companies across a range of sectors. While full access to Caroline Palomeque's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Caroline Palomeque's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Ratings, Coverage, and Performance StatisticsAnalyst RatingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings85 Last 9 YearsBuy Recommendations100.00% 85 Buy RatingsCompanies Covered16 Unique Companies Ratings Distribution85RatingsDistribution of strong buy, buy, hold, and sell ratings by Caroline Palomeque.RatingPercentageCount Strong Buy0.0%0 ratings Buy100.0%85 ratings Hold0.0%0 ratings Sell0.0%0 ratingsthe majority (100.0%) have been Buy recommendations.Best & Worst CallsBest Call0000.0%IDXGMar 2019Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%NTRPOct 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ16 companiesCaroline Palomeque, an analyst at Maxim Group, currently covers 16 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical15 companies93.8%Consumer Discretionary1 company6.3%Caroline Palomeque of Maxim Group specializes in stock coverage within the Medical sector, with additional focus on Consumer Discretionary companies.Coverage IndustriesIndustryPercentagePHARMACEUTICAL PREPARATIONS5 companies31.3%MED - BIOMED/GENE4 companies25.0%MED - DRUGS4 companies25.0%SURGICAL & MEDICAL INSTRUMENTS1 company6.3%LEISURE&REC SVS1 company6.3%MED INSTRUMENTS1 company6.3% Caroline Palomeque's Ratings History at Maxim Group Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Time Frame Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export to Excel CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsDAREDare Bioscience9/4/2025Upgrade$2.06$8.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
